The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3

Yi Yin, Jing Ni, Ming Chen, Matthew A. DiMaggio, Yinglu Guo, Shuyuan Yeh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits. In prostate cancer cells, RRR-α-vitamin E succinate (VES) inhibits cell proliferation and induces apoptosis, yet the mechanisms remain to be elucidated. We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation. Using prostate cancer models, the involvement of IGFBP-3 in the anticancer effect of VES was investigated. Experimental Design: IGFBP-3 mRNA and protein were determined by real-time PCR and Western blotting in prostate cancer cells, xenografted tumors of nude mice, and prostate tumors of transgenic adenocarcinoma mouse prostate (TRAMP) mice. The serum levels of IGFBP-3 were assessed by ELISA. The importance of IGFBP-3 in VES-mediated antitumor effects was confirmed by small interfering RNA knockdown strategy. Results: We found that VES induced IGFBP-3 mRNA and protein levels in human prostate cancer cell lines. Knockdown of IGFBP-3 by small interfering RNA attenuated VES-induced IGFBP-3 expression and VES-mediated antiproliferative and proapoptotic functions. Furthermore, administration of VES resulted in a significant therapeutic effect on LNCaP and PC3 xenografts and a preventive effect on tumorigenic progression in the TRAMP model without overt toxicity. Notably, the therapeutic and preventive efficacy of VES correlated with increased accumulation of IGFBP-3 in mouse serum as well as in the xenograft tumors and TRAMP prostate samples. Consequently, reduced proliferation and induced apoptosis were witnessed. Conclusions: VES mediates its therapeutic and preventive effects against prostate cancer at least partially through up-regulating IGFBP-3, which inhibits cell proliferation and promotes cell apoptosis.

Original languageEnglish (US)
Pages (from-to)2271-2280
Number of pages10
JournalClinical Cancer Research
Volume13
Issue number7
DOIs
StatePublished - Apr 1 2007

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Succinic Acid
Therapeutic Uses
Vitamin E
Prostatic Neoplasms
Prostate
Transgenic Mice
Adenocarcinoma
Apoptosis
Heterografts
Small Interfering RNA
Cell Proliferation
Neoplasms
Messenger RNA
Serum
Nude Mice
Real-Time Polymerase Chain Reaction
Proteins
Research Design
Up-Regulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. / Yin, Yi; Ni, Jing; Chen, Ming; DiMaggio, Matthew A.; Guo, Yinglu; Yeh, Shuyuan.

In: Clinical Cancer Research, Vol. 13, No. 7, 01.04.2007, p. 2271-2280.

Research output: Contribution to journalArticle

Yin, Yi ; Ni, Jing ; Chen, Ming ; DiMaggio, Matthew A. ; Guo, Yinglu ; Yeh, Shuyuan. / The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 7. pp. 2271-2280.
@article{aed84307fb3e46949fd525bb33e8df31,
title = "The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3",
abstract = "Purpose: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits. In prostate cancer cells, RRR-α-vitamin E succinate (VES) inhibits cell proliferation and induces apoptosis, yet the mechanisms remain to be elucidated. We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation. Using prostate cancer models, the involvement of IGFBP-3 in the anticancer effect of VES was investigated. Experimental Design: IGFBP-3 mRNA and protein were determined by real-time PCR and Western blotting in prostate cancer cells, xenografted tumors of nude mice, and prostate tumors of transgenic adenocarcinoma mouse prostate (TRAMP) mice. The serum levels of IGFBP-3 were assessed by ELISA. The importance of IGFBP-3 in VES-mediated antitumor effects was confirmed by small interfering RNA knockdown strategy. Results: We found that VES induced IGFBP-3 mRNA and protein levels in human prostate cancer cell lines. Knockdown of IGFBP-3 by small interfering RNA attenuated VES-induced IGFBP-3 expression and VES-mediated antiproliferative and proapoptotic functions. Furthermore, administration of VES resulted in a significant therapeutic effect on LNCaP and PC3 xenografts and a preventive effect on tumorigenic progression in the TRAMP model without overt toxicity. Notably, the therapeutic and preventive efficacy of VES correlated with increased accumulation of IGFBP-3 in mouse serum as well as in the xenograft tumors and TRAMP prostate samples. Consequently, reduced proliferation and induced apoptosis were witnessed. Conclusions: VES mediates its therapeutic and preventive effects against prostate cancer at least partially through up-regulating IGFBP-3, which inhibits cell proliferation and promotes cell apoptosis.",
author = "Yi Yin and Jing Ni and Ming Chen and DiMaggio, {Matthew A.} and Yinglu Guo and Shuyuan Yeh",
year = "2007",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-06-1217",
language = "English (US)",
volume = "13",
pages = "2271--2280",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3

AU - Yin, Yi

AU - Ni, Jing

AU - Chen, Ming

AU - DiMaggio, Matthew A.

AU - Guo, Yinglu

AU - Yeh, Shuyuan

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Purpose: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits. In prostate cancer cells, RRR-α-vitamin E succinate (VES) inhibits cell proliferation and induces apoptosis, yet the mechanisms remain to be elucidated. We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation. Using prostate cancer models, the involvement of IGFBP-3 in the anticancer effect of VES was investigated. Experimental Design: IGFBP-3 mRNA and protein were determined by real-time PCR and Western blotting in prostate cancer cells, xenografted tumors of nude mice, and prostate tumors of transgenic adenocarcinoma mouse prostate (TRAMP) mice. The serum levels of IGFBP-3 were assessed by ELISA. The importance of IGFBP-3 in VES-mediated antitumor effects was confirmed by small interfering RNA knockdown strategy. Results: We found that VES induced IGFBP-3 mRNA and protein levels in human prostate cancer cell lines. Knockdown of IGFBP-3 by small interfering RNA attenuated VES-induced IGFBP-3 expression and VES-mediated antiproliferative and proapoptotic functions. Furthermore, administration of VES resulted in a significant therapeutic effect on LNCaP and PC3 xenografts and a preventive effect on tumorigenic progression in the TRAMP model without overt toxicity. Notably, the therapeutic and preventive efficacy of VES correlated with increased accumulation of IGFBP-3 in mouse serum as well as in the xenograft tumors and TRAMP prostate samples. Consequently, reduced proliferation and induced apoptosis were witnessed. Conclusions: VES mediates its therapeutic and preventive effects against prostate cancer at least partially through up-regulating IGFBP-3, which inhibits cell proliferation and promotes cell apoptosis.

AB - Purpose: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits. In prostate cancer cells, RRR-α-vitamin E succinate (VES) inhibits cell proliferation and induces apoptosis, yet the mechanisms remain to be elucidated. We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation. Using prostate cancer models, the involvement of IGFBP-3 in the anticancer effect of VES was investigated. Experimental Design: IGFBP-3 mRNA and protein were determined by real-time PCR and Western blotting in prostate cancer cells, xenografted tumors of nude mice, and prostate tumors of transgenic adenocarcinoma mouse prostate (TRAMP) mice. The serum levels of IGFBP-3 were assessed by ELISA. The importance of IGFBP-3 in VES-mediated antitumor effects was confirmed by small interfering RNA knockdown strategy. Results: We found that VES induced IGFBP-3 mRNA and protein levels in human prostate cancer cell lines. Knockdown of IGFBP-3 by small interfering RNA attenuated VES-induced IGFBP-3 expression and VES-mediated antiproliferative and proapoptotic functions. Furthermore, administration of VES resulted in a significant therapeutic effect on LNCaP and PC3 xenografts and a preventive effect on tumorigenic progression in the TRAMP model without overt toxicity. Notably, the therapeutic and preventive efficacy of VES correlated with increased accumulation of IGFBP-3 in mouse serum as well as in the xenograft tumors and TRAMP prostate samples. Consequently, reduced proliferation and induced apoptosis were witnessed. Conclusions: VES mediates its therapeutic and preventive effects against prostate cancer at least partially through up-regulating IGFBP-3, which inhibits cell proliferation and promotes cell apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=34247496688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247496688&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1217

DO - 10.1158/1078-0432.CCR-06-1217

M3 - Article

C2 - 17404112

AN - SCOPUS:34247496688

VL - 13

SP - 2271

EP - 2280

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -